Novartis Pakistan company information, Employees & Contact Information

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront Novartis

Novartis bets on covalent chemistry in $1B Matchpoint deal FirstWord Pharma

Novartis gains first approval of malaria treatment for babies FirstWord Pharma

Translational medicine research at Novartis Novartis

Research and development Novartis

Payments to Healthcare Professionals Novartis

Global Health disease area research at Novartis Novartis

Therapeutic areas Novartis

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer Novartis

Coronavirus Novartis

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) Novartis

People and culture Novartis

Neuroscience research at Novartis Novartis

Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research Frontiers

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) Novartis

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline Novartis

From black holes to AI driven drug discovery – collaboration wins the day Novartis

Cardiovascular, renal and metabolic Novartis

Early careers Novartis

Novartis access principles Novartis

Sickle cell disease Novartis

Cardiovascular and metabolic disease research at Novartis Novartis

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer Novartis

Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) Novartis

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA Novartis

Our commitment to ethical and responsible use of Artificial Intelligence (AI) Novartis

Climate Novartis

US Biomedical Research internship programs Novartis

Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2 Novartis

Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness Novartis

Board of Directors Novartis

About Novartis

Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria Novartis

Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off Novartis

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease Novartis

Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation Novartis

New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases Novartis

Novartis to sell its Roche stake in a bilateral transaction to Roche Novartis

Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate Fierce Biotech

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis Novartis

Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator Novartis

Novartis and GSK announce collaboration to support scientific research into genetic diversity in Africa Novartis

Novartis expands alliance with Science 37 to advance virtual clinical trials program Novartis

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms Novartis

Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off Novartis

Novartis places heavily backloaded $1.1B bet on mystery cancer asset FirstWord Pharma

Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader Novartis

Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez) Novartis

Product sales Novartis

Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC) Novartis

Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice Novartis

Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor Novartis

Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA Novartis

Chinese infectious disease biotech Ascletis nabs Novartis exec as CSO Fierce Biotech

Fixed-income securities Novartis

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers Nature

Novartis expands its biopharmaceutical manufacturing site in Singapore Novartis

Novartis will start doing more fundamental research work in India: Vas Narasimhan Forbes India

Novartis: Innovating for the world, from India Forbes India